Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 2/20 | 0.31 |
| ▸ | CNR2 | P34972 | 2/20 | 0.31 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.30 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22406217 | 0.88 | KDM1A (0.42) | KDM1AMAOBRAB9A | |
| SCHEMBL17187995 | 0.81 | SSTR4 (0.36) | SSTR4 | |
| SCHEMBL17187996 | 0.81 | SSTR4 (0.36) | SSTR4 | |
| SCHEMBL18581645 | 0.81 | BACE1 (0.30) | SMN1; SMN2NPSR1KDM1AMAOB | |
| SCHEMBL18582039 | 0.81 | PRKCG (0.32) | SMN1; SMN2NPSR1KDM1AMAOBCYP3A4 | |
| SCHEMBL18581971 | 0.80 | CYP3A4 (0.31) | SMN1; SMN2CYP3A4HTT | |
| SCHEMBL4354026 | 0.79 | ACACB (0.34) | KDM1AMAOB | |
| SCHEMBL19857373 | 0.78 | KDM1A (0.33) | SMN1; SMN2NPSR1KDM1AMAOBSSTR4 | |
| SCHEMBL19857376 | 0.78 | KDM1A (0.33) | SMN1; SMN2NPSR1KDM1AMAOBSSTR4 | |
| SCHEMBL22227918 | 0.76 | L3MBTL1 (0.38) | SMN1; SMN2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230407285-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | DOGMA THERAPEUTICS, INC. | 2023-12-21 | — | — | US | disclosed |
| US-11603523-B2 | PCSK9 inhibitors and methods of use thereof | ASTRAZENECA AB (SE) | 2023-03-14 | — | — | US | disclosed |
| US-20220220122-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2022-07-14 | — | — | US | disclosed |
| US-20200231584-A1 | PCSK9 Inhibitors and Methods of Use Thereof | ASTRAZENECA AB (SE) | 2020-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230407285-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | PCSK9, PCSK7, PCSK6 | SMN1; SMN2 4857/4885NPSR1 1534/4885TRPV1 3961/4885 |
| US-11603523-B2 | PCSK9 inhibitors and methods of use thereof | PCSK9, PCSK7, PCSK6 | SMN1; SMN2 4857/4885NPSR1 1534/4885TRPV1 3961/4885 |
| US-20200231584-A1 | PCSK9 Inhibitors and Methods of Use Thereof | PCSK9, PCSK7, PCSK6 | SMN1; SMN2 4857/4885NPSR1 1534/4885TRPV1 3961/4885 |
| US-20220220122-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | PCSK9, PCSK7, PCSK6 | SMN1; SMN2 3651/4885NPSR1 2604/4885TRPV1 3718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.